Rafferty Asset Management LLC Cuts Holdings in Stoke Therapeutics, Inc. $STOK

Rafferty Asset Management LLC trimmed its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 31.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 35,327 shares of the company’s stock after selling 16,131 shares during the period. Rafferty Asset Management LLC owned about 0.06% of Stoke Therapeutics worth $830,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Generali Investments Management Co LLC bought a new position in shares of Stoke Therapeutics in the third quarter valued at approximately $41,000. BNP Paribas Financial Markets lifted its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the period. Osaic Holdings Inc. boosted its position in Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after purchasing an additional 5,427 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in Stoke Therapeutics by 33.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock worth $108,000 after purchasing an additional 2,384 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group raised their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Wedbush boosted their price target on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Monday, January 12th. Guggenheim initiated coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 price target for the company. Loop Capital set a $35.00 price objective on shares of Stoke Therapeutics in a report on Monday, January 5th. Finally, UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.25.

Stoke Therapeutics Stock Up 2.4%

Shares of STOK opened at $35.48 on Friday. Stoke Therapeutics, Inc. has a twelve month low of $5.35 and a twelve month high of $39.81. The stock has a market cap of $2.03 billion, a PE ratio of 52.96 and a beta of 1.07. The business’s 50-day moving average price is $32.19 and its 200-day moving average price is $28.94.

Insider Buying and Selling

In other news, Director Edward M. Md Kaye sold 13,430 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $32.27, for a total transaction of $433,386.10. Following the completion of the transaction, the director directly owned 49,124 shares in the company, valued at $1,585,231.48. The trade was a 21.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Jonathan Allan sold 3,978 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $32.28, for a total transaction of $128,409.84. Following the completion of the transaction, the general counsel directly owned 11,831 shares in the company, valued at approximately $381,904.68. The trade was a 25.16% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 9.50% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.